Literature DB >> 23019654

Pharmacogenomics and patient care: one size does not fit all.

Kathleen M Giacomini1, Sook Wah Yee, Mark J Ratain, Richard M Weinshilboum, Naoyuki Kamatani, Yusuke Nakamura.   

Abstract

The time is ripe to assess whether pharmacogenomics research--the study of the genetic basis for variation in drug response--has provided important insights into a personalized approach to prescribing and dosing medications. Here, we describe the status of the field and approaches for addressing some of the open questions in pharmacogenomics research and use of genetic testing in guiding drug therapy.

Entities:  

Mesh：

Year:  2012        PMID： 23019654      PMCID： PMC3963516          DOI： 10.1126/scitranslmed.3003471

Source DB:  PubMed          Journal:  Sci Transl Med        ISSN： 1946-6234            Impact factor:   17.956


  53 in total

1.  Clinical Pharmacogenetics Implementation Consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing.

Authors:  M V Relling; E E Gardner; W J Sandborn; K Schmiegelow; C-H Pui; S W Yee; C M Stein; M Carrillo; W E Evans; T E Klein
Journal:  Clin Pharmacol Ther       Date:  2011-01-26       Impact factor: 6.875

2.  HLA-A*3101 and carbamazepine-induced hypersensitivity reactions in Europeans.

Authors:  Mark McCormack; Ana Alfirevic; Stephane Bourgeois; John J Farrell; Dalia Kasperavičiūtė; Mary Carrington; Graeme J Sills; Tony Marson; Xiaoming Jia; Paul I W de Bakker; Krishna Chinthapalli; Mariam Molokhia; Michael R Johnson; Gerard D O'Connor; Elijah Chaila; Saud Alhusaini; Kevin V Shianna; Rodney A Radtke; Erin L Heinzen; Nicole Walley; Massimo Pandolfo; Werner Pichler; B Kevin Park; Chantal Depondt; Sanjay M Sisodiya; David B Goldstein; Panos Deloukas; Norman Delanty; Gianpiero L Cavalleri; Munir Pirmohamed
Journal:  N Engl J Med       Date:  2011-03-24       Impact factor: 91.245

3.  Genome-wide associations and functional genomic studies of musculoskeletal adverse events in women receiving aromatase inhibitors.

Authors:  James N Ingle; Daniel J Schaid; Paul E Goss; Mohan Liu; Taisei Mushiroda; Judy-Anne W Chapman; Michiaki Kubo; Gregory D Jenkins; Anthony Batzler; Lois Shepherd; Joseph Pater; Liewei Wang; Matthew J Ellis; Vered Stearns; Daniel C Rohrer; Matthew P Goetz; Kathleen I Pritchard; David A Flockhart; Yusuke Nakamura; Richard M Weinshilboum
Journal:  J Clin Oncol       Date:  2010-09-27       Impact factor: 44.544

4.  Pharmacogenomics: "noninferiority" is sufficient for initial implementation.

Authors:  R B Altman
Journal:  Clin Pharmacol Ther       Date:  2011-03       Impact factor: 6.875

Review 5.  The phenotype standardization project: improving pharmacogenetic studies of serious adverse drug reactions.

Authors:  M Pirmohamed; G P Aithal; E Behr; A Daly; D Roden
Journal:  Clin Pharmacol Ther       Date:  2011-06       Impact factor: 6.875

6.  Detecting drug interactions from adverse-event reports: interaction between paroxetine and pravastatin increases blood glucose levels.

Authors:  N P Tatonetti; J C Denny; S N Murphy; G H Fernald; G Krishnan; V Castro; P Yue; P S Tsao; P S Tsau; I Kohane; D M Roden; R B Altman
Journal:  Clin Pharmacol Ther       Date:  2011-05-25       Impact factor: 6.875

7.  Mercaptopurine therapy intolerance and heterozygosity at the thiopurine S-methyltransferase gene locus.

Authors:  M V Relling; M L Hancock; G K Rivera; J T Sandlund; R C Ribeiro; E Y Krynetski; C H Pui; W E Evans
Journal:  J Natl Cancer Inst       Date:  1999-12-01       Impact factor: 13.506

8.  Genome-wide association study identifies HLA-A*3101 allele as a genetic risk factor for carbamazepine-induced cutaneous adverse drug reactions in Japanese population.

Authors:  Takeshi Ozeki; Taisei Mushiroda; Amara Yowang; Atsushi Takahashi; Michiaki Kubo; Yuji Shirakata; Zenro Ikezawa; Masafumi Iijima; Tetsuo Shiohara; Koji Hashimoto; Naoyuki Kamatani; Yusuke Nakamura
Journal:  Hum Mol Genet       Date:  2010-12-10       Impact factor: 6.150

9.  A genome-wide study identifies HLA alleles associated with lumiracoxib-related liver injury.

Authors:  Jonathan B Singer; Steve Lewitzky; Elisabeth Leroy; Fan Yang; Xiaojun Zhao; Lloyd Klickstein; Timothy M Wright; Joanne Meyer; Charles A Paulding
Journal:  Nat Genet       Date:  2010-07-18       Impact factor: 38.330

10.  Common variants near ATM are associated with glycemic response to metformin in type 2 diabetes.

Authors:  Kaixin Zhou; Celine Bellenguez; Chris C A Spencer; Amanda J Bennett; Ruth L Coleman; Roger Tavendale; Simon A Hawley; Louise A Donnelly; Chris Schofield; Christopher J Groves; Lindsay Burch; Fiona Carr; Amy Strange; Colin Freeman; Jenefer M Blackwell; Elvira Bramon; Matthew A Brown; Juan P Casas; Aiden Corvin; Nicholas Craddock; Panos Deloukas; Serge Dronov; Audrey Duncanson; Sarah Edkins; Emma Gray; Sarah Hunt; Janusz Jankowski; Cordelia Langford; Hugh S Markus; Christopher G Mathew; Robert Plomin; Anna Rautanen; Stephen J Sawcer; Nilesh J Samani; Richard Trembath; Ananth C Viswanathan; Nicholas W Wood; Lorna W Harries; Andrew T Hattersley; Alex S F Doney; Helen Colhoun; Andrew D Morris; Calum Sutherland; D Grahame Hardie; Leena Peltonen; Mark I McCarthy; Rury R Holman; Colin N A Palmer; Peter Donnelly; Ewan R Pearson
Journal:  Nat Genet       Date:  2010-12-26       Impact factor: 38.330
View more
  22 in total

1.  Seeking Genomic Knowledge: The Case for Clinical Restraint.

Authors:  Wylie Burke; Susan Brown Trinidad; Ellen Wright Clayton
Journal:  Hastings Law J       Date:  2013-08-01

Review 2.  Within and beyond the communal turn to informed consent in industry-sponsored pharmacogenetics research: merits and challenges of community advisory boards.

Authors:  Hojjat Soofi; Evert van Leeuwen
Journal:  J Community Genet       Date:  2016-08-05

3.  Inherited NUDT15 variant is a genetic determinant of mercaptopurine intolerance in children with acute lymphoblastic leukemia.

Authors:  Jun J Yang; Wendy Landier; Wenjian Yang; Chengcheng Liu; Lindsey Hageman; Cheng Cheng; Deqing Pei; Yanjun Chen; Kristine R Crews; Nancy Kornegay; F Lennie Wong; William E Evans; Ching-Hon Pui; Smita Bhatia; Mary V Relling
Journal:  J Clin Oncol       Date:  2015-01-26       Impact factor: 44.544

Review 4.  Pharmacogenomics in early-phase clinical development.

Authors:  Tal Burt; Savita Dhillon
Journal:  Pharmacogenomics       Date:  2013-07       Impact factor: 2.533

Review 5.  Genomics and Pharmacogenomics of Salt-sensitive Hypertension.

Authors:  Ines Armando; Van Anthony M Villar; Pedro A Jose
Journal:  Curr Hypertens Rev       Date:  2015

6.  Genomics and pharmacogenomics of salt-sensitive hypertension Minireview.

Authors:  Ines Armando; Van Anthony M Villar; Pedro A Jose
Journal:  Curr Hypertens Rev       Date:  2015

Review 7.  Expression quantitative trait analyses to identify causal genetic variants for type 2 diabetes susceptibility.

Authors:  Swapan Kumar Das; Neeraj Kumar Sharma
Journal:  World J Diabetes       Date:  2014-04-15

Review 8.  Pharmacogenomics: Precision Medicine and Drug Response.

Authors:  Richard M Weinshilboum; Liewei Wang
Journal:  Mayo Clin Proc       Date:  2017-11-01       Impact factor: 7.616

Review 9.  Pharmacogenomics in clinical practice and drug development.

Authors:  Andrew R Harper; Eric J Topol
Journal:  Nat Biotechnol       Date:  2012-11-08       Impact factor: 54.908

10.  Implementing Pharmacogenomics Testing: Single Center Experience at Arkansas Children's Hospital.

Authors:  Pritmohinder S Gill; Feliciano B Yu; Patricia A Porter-Gill; Bobby L Boyanton; Judy C Allen; Jason E Farrar; Aravindhan Veerapandiyan; Parthak Prodhan; Kevin J Bielamowicz; Elizabeth Sellars; Andrew Burrow; Joshua L Kennedy; Jeffery L Clothier; David L Becton; Don Rule; G Bradley Schaefer
Journal:  J Pers Med       Date:  2021-05-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.